Forgot Password?
Return to Course Listing

CME: Top strategies in the management of advanced renal cell carcinoma (RCC)


Activity Description / Statement of Need:

In this online, self-learning activity:

Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in 79,000 people and account for close to 14,000 deaths in the U.S. per year. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 14%, representing an area of ongoing clinical need. Treatment selection in advanced, clear cell RCC treatment depends on prognostic scoring and may include mono- or combination therapy with immunotherapy and an antiangiogenic agent, and many of the same agents are used to treat advanced, non-clear cell RCC.

Target Audience:

HCPs including: Medical oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RCC.

Commercial Support Disclosure: This program is supported by an educational grant from Exelixis.

This activity is free of charge.

Release Date: February 22, 2023 -- Expiration Date: February 22, 2024

Faculty: Nazli Dizman, MD


Faculty introduction, disclosures


Introductory content

  • Epidemiology
  • Histopathology and prognosis/staging 

Treatment of advanced RCC

  • Treatment goals
  • Factors impacting decision-making: favorable vs. intermediate- or poor-risk advanced RCC; presence or absence of major, symptomatic disease burden
  • Present pharmacotherapy, clinical trial findings, and guideline updates 
    • Mono- vs. combination therapy
    • Immunotherapy and/or antiangiogenic therapy
    • Next-line therapies
    • Clear cell advanced RCC
    • Initial therapy
    • Non-clear cell advanced RCC
    • Assessment of response
  • Emerging therapies 
  • Safety and toxicity profiles of present and emerging agents
  • Patient case(s) 


Summary, conclusions, and best practice recap


Learning Objectives

By the end of the session the participant will be able to:

  • Recall the pathophysiology of advanced RCC such that it informs treatment mechanisms.
  • Describe: present and emerging treatment options for advanced RCC; their place or anticipated in therapy; and risk-benefit profiles.
  • Formulate a treatment plan for a patient with advanced RCC.


ACCME Activity #202386993


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Nazli Dizman, MD, Department of Medical Oncology & Experimental Therapeutics, City of Hope National Medical Center, has received financial compensation from Vivreon GastroScience for consulting work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Exelixis.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Myeloma bone disease: Monitoring and management

Targeting chronic lymphocytic leukemia (CLL): Approaches to care at different stages of the disease

Updates in multiple myeloma (MM): Determining next steps forward in the face of relapse

Prediction and management of bone complications in prostate cancer